Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Yes, both are recognized risks: Zepbound (tirzepatide) carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent studies, and pancreatitis has been reported in people using it, though both events appear rare. Warning signs of pancreatitis include severe, persistent upper abdominal pain that may radiate to the back, often with nausea or vomiting, while possible thyroid tumor signs include a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath. Risk is higher for anyone with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, prior pancreatitis, gallbladder disease, or heavy alcohol use, and other medications can raise it further. There are several important factors to consider, including which symptoms require stopping the drug and seeking urgent care, so review the complete details below rather than the summary alone.
If you are on Zepbound and noticing abdominal pain, ongoing vomiting, neck swelling, or voice changes, the fastest way to sort routine side effects from something serious is a free, instant, online symptom check that reviews your symptoms and history in minutes and points you toward the right next step, whether that is calling your prescriber, urgent care, or the emergency room.
Last reviewed for medical accuracy: 09/13/2026
Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management and type 2 diabetes. As with any prescription drug, it can cause side effects. You may be wondering specifically about the risks of pancreatitis or thyroid cancer when taking Zepbound. Below is a balanced, evidence-based overview to help you understand what is known so far and when to seek medical advice.
Zepbound is a once-weekly injectable medication that acts on two gut hormones (GIP and GLP-1) to:
Its dual-action mechanism generally leads to significant weight loss and better glycemic control compared to some older medications.
Most people tolerate Zepbound well, but gastrointestinal reactions are the most frequent. In clinical trials, participants commonly reported:
These side effects tend to occur early in treatment and often decrease over time as the body adjusts.
Pancreatitis (inflammation of the pancreas) has been associated with some GLP-1 receptor agonists in rare cases. For Zepbound:
You may have a higher chance of pancreatitis if you have:
Contact your healthcare provider immediately if you experience:
If you think you might be having pancreatitis, do not wait. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker and speak to a doctor or get emergency care if pain is severe.
In long-term animal studies of tirzepatide and other GLP-1 based drugs, researchers observed thyroid C-cell tumors (including adenomas and carcinomas) in rodents. Key points:
Because of the rodent findings, Zepbound is not recommended for:
Before starting Zepbound, your doctor will review your personal and family medical history to make sure it’s safe.
While on Zepbound, report any of these warning signs promptly:
If you notice anything unusual, you might want to try a free, online symptom check, using the doctor approved Ubie Symptom Checker and then follow up with your physician for further evaluation.
Zepbound offers many patients significant benefits:
However, no drug is without risk. The absolute incidence of pancreatitis or thyroid tumors in humans taking Zepbound appears very low or unconfirmed. Still, staying informed and vigilant helps you catch any rare complications early.
Any of the following warrant prompt medical attention:
If symptoms seem serious or life-threatening, call 911 or go to the nearest emergency department. For non-urgent concerns, you might first try a free, online symptom check, using the doctor approved Ubie Symptom Checker and then follow up with your healthcare provider.
Zepbound can be a powerful tool for weight management and blood sugar control. While worries about pancreatitis or thyroid cancer are not unfounded, the real-world incidence of these events in people taking Zepbound remains extremely low or unconfirmed. Awareness and early reporting are key.
Always discuss any concerns or unusual symptoms with your doctor. They can help weigh the benefits and risks in the context of your health history and guide you toward the safest, most effective treatment plan. If you’re ever in doubt, speak to a doctor—your health is too important to leave to chance.
(References)
* Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018 Dec;18:3-14. doi: 10.1016/j.molmet.2018.09.009. Epub 2018 Oct 3. PMID: 30473097; PMCID: PMC6308032.
* Gettman L. New Drug: Tirzepatide (Mounjaro(™)). Sr Care Pharm. 2023 Feb 1;38(2):50-62. doi: 10.4140/TCP.n.2023.50. PMID: 36751934.
* Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. doi: 10.1210/jendso/bvad016. Epub 2023 Jan 26. PMID: 36789109; PMCID: PMC9915969.
* McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic Drug-Related Weight Gain and Its Treatment. Am J Psychiatry. 2024 Jan 1;181(1):26-38. doi: 10.1176/appi.ajp.20230922. PMID: 38161305.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. doi: 10.3389/fendo.2024.1431292. Epub 2024 Jul 24. PMID: 39114288; PMCID: PMC11304055.
* Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, Heymsfield SB. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025 Jan;26(1):e13841. doi: 10.1111/obr.13841. Epub 2024 Sep 19. PMID: 39295512; PMCID: PMC11611443.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025 Nov 18;86(20):1805-1819. doi: 10.1016/j.jacc.2025.08.027. Epub 2025 Aug 27. PMID: 40892610.
* Ko A, Chang YC, Bahar F, Wang TH, Xanthavanij N, Yu CC, Hsieh RJ, See XY, Lo SW, Song J, Hsia YP, Chiang CH, Xu X, Lin S, Chiang CH. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. Ann Intern Med. 2026 Feb;179(2):216-229. doi: 10.7326/ANNALS-25-02237. Epub 2025 Dec 9. PMID: 41359966.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.